Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting crucial coinhibitory pathways. Pathways involving PD-1/PD-L1 and CTLA-4 are essential for immune homeostasis but are frequently exploited by tumors to evade immune surveillance. ICIs block these interactions, unleashing a potent antitumor immune response. However, broad clinical efficacy is limited by low response rates, immune-related adverse events, and the pervasive challenge of primary or acquired resistance. This review summarizes the fundamental molecular mechanisms of key checkpoints (PD-1/PD-L1, CTLA-4, TIM-3) and highlights recent clinical progress in ICI monotherapies and combination strategies. We systematically explore multifaceted mechanisms of resistance, encompassing both tumor-intrinsic and extrinsic factors. Furthermore, we outline novel therapeutic approaches being designed to overcome this resistance. Finally, we discuss promising predictive biomarkers and precision immuno-oncology strategies. This review provides a critical framework for navigating the current landscape and offers a rationale to guide the future development of effective combination therapies to improve patient outcomes.

Keywords

immune checkpoints / immune combination therapies / immune escape / immune resistance / immunotherapy / tumor microenvironment

References

[1] P. S. Adusumilli, E. Cha, M. Cornfeld, et al., “New Cancer Immunotherapy Agents in Development: A Report From an Associated Program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016,” Journal for Immunotherapy of Cancer 5 (2017): 50.

[2] Y. Xu, Z. Xiang, M. Alnaggar, et al., “Allogeneic Vγ9Vδ2 T-Cell Immunotherapy Exhibits Promising Clinical Safety and Prolongs the Survival of Patients With Late-Stage Lung or Liver Cancer,” Cellular & Molecular Immunology 18, no. 2 (2021): 427–439.

[3] Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, “Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, Upon Programmed Cell Death,” The EMBO Journal 11, no. 11 (1992): 3887–3895.

[4] F. S. Hodi, S. J. O'Day, D. F. McDermott, et al., “Improved Survival With Ipilimumab in Patients With Metastatic Melanoma,” The New England Journal of Medicine 363, no. 8 (2010): 711–723.

[5] S. Arora, S. Balasubramaniam, W. Zhang, et al., “FDA Approval Summary: Pembrolizumab Plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review Under Project Orbis,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 26, no. 19 (2020): 5062–5067.

[6] J. Paik, “Nivolumab Plus Relatlimab: First Approval,” Drugs 82, no. 8 (2022): 925–931.

[7] P. Schmid, J. Cortes, L. Pusztai, et al., “Pembrolizumab for Early Triple-Negative Breast Cancer,” The New England Journal of Medicine 382, no. 9 (2020): 810–821.

[8] J. Cortes, H. S. Rugo, D. W. Cescon, et al., “Pembrolizumab Plus Chemotherapy in Advanced Triple-Negative Breast Cancer,” The New England Journal of Medicine 387, no. 3 (2022): 217–226.

[9] P. Schmid, J. Cortes, R. Dent, et al., “Event-Free Survival With Pembrolizumab in Early Triple-Negative Breast Cancer,” The New England Journal of Medicine 386, no. 6 (2022): 556–567.

[10] M. Jin, J. Fang, J. Peng, et al., “PD-1/PD-L1 Immune Checkpoint Blockade in Breast Cancer: Research Insights and Sensitization Strategies,” Molecular Cancer 23 (2024): 266.

[11] M. Vesely, T. Zhang, and L. Chen, “Resistance Mechanisms to Anti-PD Cancer Immunotherapy,” Annual Review of Immunology 40 (2022): 45–74.

[12] T. Li, C. Zhang, G. Zhao, et al., “IGFBP2 Regulates PD-L1 Expression by Activating the EGFR-STAT3 Signaling Pathway in Malignant Melanoma,” Cancer Letters 477 (2020): 19–30.

[13] X. Xiao, J. Shi, C. He, et al., “ERK and USP5 Govern PD-1 Homeostasis via Deubiquitination to Modulate Tumor Immunotherapy,” Nature Communications 14, no. 1 (2023): 2859.

[14] K. Gao, Q. Shi, Y. Gu, et al., “SPOP Mutations Promote Tumor Immune Escape in Endometrial Cancer via the IRF1-PD-L1 Axis,” Cell Death and Differentiation 30, no. 2 (2023): 475–487.

[15] T. André, E. Elez, H. J. Lenz, et al., “Nivolumab Plus Ipilimumab Versus Nivolumab in Microsatellite Instability-High Metastatic Colorectal Cancer (CheckMate 8HW): A Randomised, Open-Label, Phase 3 Trial,” Lancet 405, no. 10476 (2025): 383–395.

[16] J. Chen, Z. Amoozgar, X. Liu, et al., “Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy,” Cancer Immunology Research 12, no. 4 (2024): 400–412.

[17] T. Yokosuka, M. Takamatsu, W. Kobayashi-Imanishi, A. Hashimoto-Tane, M. Azuma, and T. Saito, “Programmed Cell Death 1 Forms Negative Costimulatory Microclusters That Directly Inhibit T Cell Receptor Signaling by Recruiting Phosphatase SHP2,” Journal of Experimental Medicine 209, no. 6 (2012): 1201–1217.

[18] X. Zhang, J. D. Schwartz, X. Guo, et al., “Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1,” Immunity 20, no. 3 (2004): 337–347.

[19] E. A. Philips, J. Liu, A. Kvalvaag, et al., “Transmembrane Domain-Driven PD-1 Dimers Mediate T Cell Inhibition,” Science Immunology 9, no. 93 (2024): eade6256.

[20] E. Hui, J. Cheung, J. Zhu, et al., “T Cell Costimulatory Receptor CD28 Is a Primary Target for PD-1-Mediated Inhibition,” Science 355, no. 6332 (2017): 1428–1433.

[21] K. Hofmeyer, H. Jeon, and X. Zang, “The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion,” Journal of Biomedicine and Biotechnology 2011 (2011): 451694.

[22] W. Piao, L. Li, V. Saxena, et al., “PD-L1 Signaling Selectively Regulates T Cell Lymphatic Transendothelial Migration,” Nature Communications 13, no. 1 (2022): 2176.

[23] A. Salmaninejad, S. F. Valilou, A. G. Shabgah, et al., “PD-1/PD-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy,” Journal of Cellular Physiology 234, no. 10 (2019): 16824–16837.

[24] J. A. Turner, E. Stephen-Victor, S. Wang, et al., “Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity,” Immunity 53, no. 6 (2020): 1202–1214.e6.

[25] L. M. Francisco, V. H. Salinas, K. E. Brown, et al., “PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells,” Journal of Experimental Medicine 206, no. 13 (2009): 3015–3029.

[26] S. R. Gordon, R. L. Maute, B. W. Dulken, et al., “PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity,” Nature 545, no. 7655 (2017): 495–499.

[27] S. Sauer, L. Bruno, A. Hertweck, et al., “T Cell Receptor Signaling Controls Foxp3 Expression via PI3K, Akt, and mTOR,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 22 (2008): 7797–7802.

[28] Y. Hu and C. Liu, “SIRT3-SUMO Regulated Treg Cell Differentiation and Asthma Development by Mediating N-Glycosylation Through the FAO Pathway,” Cell Biology and Toxicology 41, no. 1 (2025): 164.

[29] C. McDonald-Hyman, E. G. Aguilar, E. B. Compeer, et al., “Acetyl-CoA Carboxylase 1 Inhibition Increases Treg Metabolism and Graft-Versus-Host Disease Treatment Efficacy via Mitochondrial Fusion,” Journal of Clinical Investigation 135, no. 23 (2025): e182480.

[30] Z. Chi, Y. Lu, Y. Yang, B. Li, and P. Lu, “Transcriptional and Epigenetic Regulation of PD-1 Expression,” Cellular and Molecular Life Sciences 78, no. 7 (2021): 3239–3246.

[31] A. Bally, J. Austin, and J. Boss, “Genetic and Epigenetic Regulation of PD-1 Expression,” Journal of Immunology 196, no. 6 (2016): 2431–2437.

[32] K. J. Oestreich, H. Yoon, R. Ahmed, and J. M. Boss, “NFATc1 Regulates PD-1 Expression Upon T Cell Activation,” Journal of Immunology 181, no. 7 (2008): 4832–4839.

[33] J. W. Austin, P. Lu, P. Majumder, R. Ahmed, and J. M. Boss, “STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 Through Multiple Novel Regulatory Regions in Murine T Cells,” Journal of Immunology 192, no. 10 (2014): 4876–4886.

[34] S. Terawaki, S. Chikuma, S. Shibayama, et al., “IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity,” Journal of Immunology 186, no. 5 (2011): 2772–2779.

[35] P. Lu, B. A. Youngblood, J. W. Austin, et al., “Blimp-1 Represses CD8 T Cell Expression of PD-1 Using a Feed-Forward Transcriptional Circuit During Acute Viral Infection,” Journal of Experimental Medicine 211, no. 3 (2014): 515–527.

[36] C. Kao, K. J. Oestreich, M. A. Paley, et al., “Transcription Factor T-Bet Represses Expression of the Inhibitory Receptor PD-1 and Sustains Virus-Specific CD8+ T Cell Responses During Chronic Infection,” Nature Immunology 12, no. 7 (2011): 663–671.

[37] B. Youngblood, A. Noto, F. Porichis, et al., “Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells,” Journal of Immunology 191, no. 2 (2013): 540–544.

[38] X. Meng, X. Liu, X. Guo, et al., “FBXO38 Mediates PD-1 Ubiquitination and Regulates Anti-Tumour Immunity of T Cells,” Nature 564, no. 7734 (2018): 130–135.

[39] N. Zhang, M. Li, X. Xu, et al., “Loss of Core Fucosylation Enhances the Anticancer Activity of Cytotoxic T Lymphocytes by Increasing PD-1 Degradation,” European Journal of Immunology 50, no. 11 (2020): 1820–1833.

[40] M. Okada, S. Chikuma, T. Kondo, et al., “Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-Tumor Immune Responses of T Cells,” Cell Reports 20, no. 5 (2017): 1017–1028.

[41] X. Wang, Q. He, H. Shen, et al., “TOX Promotes the Exhaustion of Antitumor CD8(+) T Cells by Preventing PD1 Degradation in Hepatocellular Carcinoma,” Journal of Hepatology 71, no. 4 (2019): 731–741.

[42] M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, “PD-1 and Its Ligands in Tolerance and Immunity,” Annual Review of Immunology 26 (2008): 677–704.

[43] D. Y. Lin, Y. Tanaka, M. Iwasaki, et al., “The PD-1/PD-L1 Complex Resembles the Antigen-Binding Fv Domains of Antibodies and T Cell Receptors,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 8 (2008): 3011–3016.

[44] A. V. Kornepati, J. T. Boyd, C. E. Murray, et al., “Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality,” Cancer Research 82, no. 11 (2022): 2156–2170.

[45] X. He and C. Xu, “Immune Checkpoint Signaling and Cancer Immunotherapy,” Cell Research 30, no. 8 (2020): 660–669.

[46] A. Chaudhri, Y. Xiao, A. N. Klee, X. Wang, B. Zhu, and G. J. Freeman, “PD-L1 Binds to B7-1 Only in Cis on the Same Cell Surface,” Cancer Immunology Research 6, no. 8 (2018): 921–929.

[47] D. Sugiura, T. Maruhashi, I. Okazaki, et al., “Restriction of PD-1 Function by Cis-PD-L1/CD80 Interactions Is Required for Optimal T Cell Responses,” Science 364, no. 6440 (2019): 558–566.

[48] Y. Zhang, Q. Song, K. Cassady, et al., “Blockade of Trans PD-L1 Interaction With CD80 Augments Antitumor Immunity,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 16 (2023): e2205085120.

[49] Y. Liu, Z. Yang, S. Wang, et al., “Nuclear PD-L1 Compartmentalization Suppresses Tumorigenesis and Overcomes Immunocheckpoint Therapy Resistance in Mice via Histone macroH2A1,” Journal of Clinical Investigation 134, no. 22 (2024): e181314.

[50] Y. Wang, Y. Zhou, L. Yang, et al., “Challenges Coexist With Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 1 (2024): e2303175.

[51] H. Wang, H. Yao, C. Li, et al., “HIP1R Targets PD-L1 to Lysosomal Degradation to Alter T Cell-Mediated Cytotoxicity,” Nature Chemical Biology 15, no. 1 (2019): 42–50.

[52] A. Satelli, I. S. Batth, Z. Brownlee, et al., “Potential Role of Nuclear PD-L1 Expression in Cell-Surface Vimentin Positive Circulating Tumor Cells as a Prognostic Marker in Cancer Patients,” Scientific Reports 6 (2016): 28910.

[53] W. Du, J. Zhu, Y. Zeng, et al., “KPNB1-Mediated Nuclear Translocation of PD-L1 Promotes Non-Small Cell Lung Cancer Cell Proliferation via the Gas6/MerTK Signaling Pathway,” Cell Death and Differentiation 28, no. 4 (2021): 1284–1300.

[54] J. Yu, A. Zhuang, X. Gu, et al., “Nuclear PD-L1 Promotes EGR1-Mediated Angiogenesis and Accelerates Tumorigenesis,” Cell Discovery 9, no. 1 (2023): 33.

[55] M. Theodoraki, S. S. Yerneni, T. K. Hoffmann, W. E. Gooding, and T. L. Whiteside, “Clinical Significance of PD-L1(+) Exosomes in Plasma of Head and Neck Cancer Patients,” Clinical Cancer Research 24, no. 4 (2018): 896–905.

[56] M. Poggio, T. Hu, C. Pai, et al., “Suppression of Exosomal PD-L1 Induces Systemic Anti-Tumor Immunity and Memory,” Cell 177, no. 2 (2019): 414–427.e13.

[57] J. Yang, J. Chen, H. Liang, and Y. Yu, “Nasopharyngeal Cancer Cell-Derived Exosomal PD-L1 Inhibits CD8+ T-Cell Activity and Promotes Immune Escape,” Cancer Science 113, no. 9 (2022): 3044–3054.

[58] G. Chen, A. C. Huang, W. Zhang, et al., “Exosomal PD-L1 Contributes to Immunosuppression and Is Associated With Anti-PD-1 Response,” Nature 560, no. 7718 (2018): 382–386.

[59] F. Ma, X. Liu, Y. Zhang, et al., “Tumor Extracellular Vesicle-Derived PD-L1 Promotes T Cell Senescence Through Lipid Metabolism Reprogramming,” Science Translational Medicine 17, no. 785 (2025): eadm7269.

[60] I. Zerdes, A. Matikas, J. Bergh, G. Z. Rassidakis, and T. Foukakis, “Genetic, Transcriptional and Post-Translational Regulation of the Programmed Death Protein Ligand 1 in Cancer: Biology and Clinical Correlations,” Oncogene 37, no. 34 (2018): 4639–4661.

[61] B. Liu, Y. Wu, A. Xiang, et al., “The Hexosamine Biosynthetic Pathway Drives Tumor Immune Evasion via Translational Control of PD-L1 at the Elongation Level,” Cell Reports 44, no. 9 (2025): 116249.

[62] P. Srivastava, M. Rütter, G. M. Antoniraj, Y. Ventura, and A. David, “Mesoporous Silica Nanoparticles With Extra-Large Pores for Boosting Antigen Presentation and PD-L1 Immune Checkpoint Blockade,” ACS Applied Bio Materials 8, no. 11 (2025): 9864–9874.

[63] Y. Li, J. Zhu, F. Zhai, et al., “LMNB2-Mediated High PD-L1 Transcription Triggers the Immune Escape of Hepatocellular Carcinoma,” Cell Death Discovery 11, no. 1 (2025): 269.

[64] X. Wang, X. Yang, L. Xing, et al., “CircLRBA Promotes Epithelial-Mesenchymal Transition, Immune Evasion, Chemoimmunotherapy Resistance and Metastasis Through Stabilizing Twist1,” Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 48 (2025): e08918.

[65] S. Liu, Y. Pan, W. Liu, et al., “Lactylation-Driven MVP Upregulation Boosts Immunotherapy Resistance by Inhibiting PD-L1 Degradation in Hepatocellular Carcinoma,” Journal for ImmunoTherapy of Cancer 13, no. 9 (2025): e012230.

[66] T. Iida, H. Ohno, C. Nakaseko, et al., “Regulation of Cell Surface Expression of CTLA-4 by Secretion of CTLA-4-Containing Lysosomes Upon Activation of CD4+ T Cells,” Journal of Immunology 165, no. 9 (2000): 5062–5068.

[67] E. Valk, C. Rudd, and H. Schneider, “CTLA-4 Trafficking and Surface Expression,” Trends in Immunology 29, no. 6 (2008): 272–279.

[68] D. Oyewole-Said, V. Konduri, J. Vazquez-Perez, S. A. Weldon, J. M. Levitt, and W. K. Decker, “Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types,” Frontiers in Immunology 11 (2020): 608024.

[69] M. M. Muthana, X. Du, M. Liu, et al., “CTLA-4 Antibody-Drug Conjugate Reveals Autologous Destruction of B-Lymphocytes Associated With Regulatory T Cell Impairment,” Elife 12 (2023): RP87281.

[70] P. Do, K. A. Beckwith, C. Cheney, et al., “Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells,” Journal of Immunology 202, no. 9 (2019): 2806–2816.

[71] D. Quandt, H. Hoff, M. Rudolph, S. Fillatreau, and M. C. Brunner-Weinzierl, “A New Role of CTLA-4 on B Cells in Thymus-Dependent Immune Responses in Vivo,” Journal of Immunology 179, no. 11 (2007): 7316–7324.

[72] Y. Chen and H. Shi, “CD28/CTLA-4–CD80/CD86 and ICOS–B7RP-1 Costimulatory Pathway in Bronchial Asthma,” Allergy 61, no. 1 (2006): 15–26.

[73] W. Teft, M. Kirchhof, and J. Madrenas, “A Molecular Perspective of CTLA-4 Function,” Annual Review of Immunology 24 (2006): 65–97.

[74] K. Chattopadhyay, E. Lazar-Molnar, Q. Yan, et al., “Sequence, Structure, Function, Immunity: Structural Genomics of Costimulation,” Immunological Reviews 229, no. 1 (2009): 356–386.

[75] J. Egen, M. Kuhns, and J. Allison, “CTLA-4: New Insights Into Its Biological Function and Use in Tumor Immunotherapy,” Nature Immunology 3, no. 7 (2002): 611–618.

[76] K. Wing, Y. Onishi, P. Prieto-Martin, et al., “CTLA-4 Control Over Foxp3+ Regulatory T Cell Function,” Science 322, no. 5899 (2008): 271–275.

[77] P. S. Linsley, J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach, “Human B7-1 (CD80) and B7-2 (CD86) Bind With Similar Avidities but Distinct Kinetics to CD28 and CTLA-4 Receptors,” Immunity 1, no. 9 (1994): 793–801.

[78] J. L. Greene, G. M. Leytze, J. Emswiler, et al., “Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions,” Journal of Biological Chemistry 271, no. 43 (1996): 26762–26771.

[79] A. Kennedy, E. Waters, B. Rowshanravan, et al., “Differences in CD80 and CD86 Transendocytosis Reveal CD86 as a Key Target for CTLA-4 Immune Regulation,” Nature Immunology 23, no. 9 (2022): 1365–1378.

[80] F. Fallarino, U. Grohmann, K. W. Hwang, et al., “Modulation of Tryptophan Catabolism by Regulatory T Cells,” Nature Immunology 4, no. 12 (2003): 1206–1212.

[81] D. H. Munn, E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor, “Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism,” Journal of Experimental Medicine 189, no. 9 (1999): 1363–1372.

[82] U. Grohmann, “Tolerance, DCs and Tryptophan: Much Ado About IDO,” Trends in Immunology 24, no. 5 (2003): 242–248.

[83] U. Grohmann, C. Orabona, F. Fallarino, et al., “CTLA-4-Ig Regulates Tryptophan Catabolism in Vivo,” Nature Immunology 3, no. 11 (2002): 1097–1101.

[84] F. Fallarino, U. Grohmann, C. Vacca, et al., “T Cell Apoptosis by Tryptophan Catabolism,” Cell Death and Differentiation 9, no. 10 (2002): 1069–1077.

[85] M. K. Oaks, K. M. Hallett, R. Penwell, E. C. Stauber, S. J. Warren, and A. J. Tector, “A Native Soluble Form of CTLA-4,” Cellular Immunology 201, no. 2 (2000): 144–153.

[86] F. J. Ward, L. N. Dahal, S. K. Wijesekera, et al., “The Soluble Isoform of CTLA-4 as a Regulator of T-Cell Responses,” European Journal of Immunology 43, no. 5 (2013): 1274–1285.

[87] V. Kalia, L. Penny, Y. Yuzefpolskiy, F. Baumann, and S. Sarkar, “Quiescence of Memory CD8(+) T Cells Is Mediated by Regulatory T Cells Through Inhibitory Receptor CTLA-4,” Immunity 42, no. 6 (2015): 1116–1129.

[88] R. Zappasodi, I. Serganova, I. J. Cohen, et al., “CTLA-4 Blockade Drives Loss of T(reg) Stability in Glycolysis-Low Tumours,” Nature 591, no. 7851 (2021): 652–658.

[89] P. Sage, A. Paterson, S. Lovitch, and A. Sharpe, “The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells,” Immunity 41, no. 6 (2014): 1026–1039.

[90] X. Chen, M. Yang, Y. Huang, J. Tu, Y. Cai, and X. Yuan, “Molecular Mechanisms Underlying the Abscopal Effect Induced by Radiotherapy and Its Synergistic Translational Potential With Immunotherapy,” Therapeutic Advances in Medical Oncology 17 (2025): 17588359251387534.

[91] V. Szentgyörgyi, L. M. Lueck, D. Overwijn, et al., “Arf1-Dependent LRBA Recruitment to Rab4 Endosomes is Required for Endolysosome Homeostasis,” Journal of Cell Biology 223, no. 11 (2024): e202401167.

[92] M. Zhang, J. Li, K. Yan, et al., “pH-Dependent Dissociation From CTLA-4 in Early Endosomes Improves Both Safety and Antitumor Activity of Anti-CTLA-4 Antibodies,” Proceedings of the National Academy of Sciences of the United States of America 122, no. 8 (2025): e2422731122.

[93] X. Wang, J. He, G. Ding, Y. Tang, and Q. Wang, “Overcoming Resistance to PD-1 and CTLA-4 Blockade Mechanisms and Therapeutic Strategies,” Frontiers in Immunology 16 (2025): 1688699.

[94] X. Tai, F. Van Laethem, L. Pobezinsky, et al., “Basis of CTLA-4 Function in Regulatory and Conventional CD4(+) T Cells,” Blood 119, no. 22 (2012): 5155–5163.

[95] B. Rowshanravan, N. Halliday, and D. Sansom, “CTLA-4: A Moving Target in Immunotherapy,” Blood 131, no. 1 (2018): 58–67.

[96] K. O. Dixon, M. Tabaka, M. A. Schramm, et al., “TIM-3 Restrains Anti-Tumour Immunity by Regulating Inflammasome Activation,” Nature 595, no. 7865 (2021): 101–106.

[97] L. Monney, C. A. Sabatos, J. L. Gaglia, et al., “Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease,” Nature 415, no. 6871 (2002): 536–541.

[98] C. Santiago, A. Ballesteros, L. Martínez-Muñoz, et al., “Structures of T Cell Immunoglobulin Mucin Protein 4 Show a Metal-Ion-Dependent Ligand Binding Site Where Phosphatidylserine Binds,” Immunity 27, no. 6 (2007): 941–951.

[99] K. Dixon, G. Lahore, and V. Kuchroo, “Beyond T Cell Exhaustion: TIM-3 Regulation of Myeloid Cells,” Science Immunology 9, no. 93 (2024): eadf2223.

[100] L. Bod, Y. Kye, J. Shi, et al., “B-Cell-Specific Checkpoint Molecules That Regulate Anti-Tumour Immunity,” Nature 619, no. 7969 (2023): 348–356.

[101] W. Zhong, X. Liu, Z. Zhu, Q. Li, and K. Li, “High Levels of Tim-3(+)Foxp3(+)Treg Cells in the Tumor Microenvironment Is a Prognostic Indicator of Poor Survival of Diffuse Large B Cell Lymphoma Patients,” International Immunopharmacology 96 (2021): 107662.

[102] Y. Asahina, S. Kamitori, T. Takao, N. Nishi, and H. Hojo, “Chemoenzymatic Synthesis of the Immunoglobulin Domain of Tim-3 Carrying a Complex-Type N-Glycan by Using a One-Pot Ligation,” Angewandte Chemie 52, no. 37 (2013): 9733–9737.

[103] Y. Kikushige, “TIM-3 in Normal and Malignant Hematopoiesis: Structure, Function, and Signaling Pathways,” Cancer Science 112, no. 9 (2021): 3419–3426.

[104] R. Ferris, B. Lu, and L. Kane, “Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion,” Journal of Immunology 193, no. 4 (2014): 1525–1530.

[105] M. Rangachari, C. Zhu, K. Sakuishi, et al., “Bat3 Promotes T Cell Responses and Autoimmunity by Repressing Tim-3–mediated Cell Death and Exhaustion,” Nature Medicine 18, no. 9 (2012): 1394–1400.

[106] S. Chiba, M. Baghdadi, H. Akiba, et al., “Tumor-Infiltrating DCs Suppress Nucleic Acid-Mediated Innate Immune Responses Through Interactions Between the Receptor TIM-3 and the Alarmin HMGB1,” Nature Immunology 13, no. 9 (2012): 832–842.

[107] Y. Huang, C. Zhu, Y. Kondo, et al., “CEACAM1 Regulates TIM-3-Mediated Tolerance and Exhaustion,” Nature 517, no. 7534 (2015): 386–390.

[108] C. M. Smith, A. Li, N. Krishnamurthy, and M. A. Lemmon, “Phosphatidylserine Binding Directly Regulates TIM-3 Function,” Biochemical Journal 478, no. 17 (2021): 3331–3349.

[109] Y. Che, Z. Luo, Y. Cao, et al., “Integrated Pathological Analysis to Develop a Gal-9 Based Immune Survival Stratification to Predict the Outcome of Lung Large Cell Neuroendocrine Carcinoma and Its Usefulness in Immunotherapy,” International Journal of Biological Sciences 18, no. 15 (2022): 5913–5927.

[110] J. Jiao, D. Jiao, F. Yang, et al., “Galectin-9 Expression Predicts Poor Prognosis in Hepatitis B Virus-Associated Hepatocellular Carcinoma,” Aging (Albany NY) 14, no. 4 (2022): 1879–1890.

[111] P. Chen, L. Zhang, W. Zhang, et al., “Galectin-9-Based Immune Risk Score Model Helps to Predict Relapse in Stage I-III Small Cell Lung Cancer,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e001391.

[112] L. Liang, Y. Zhang, Y. Shen, et al., “Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease,” Frontiers in Cell and Developmental Biology 9 (2021): 628128.

[113] R. Yang, L. Sun, C. Li, et al., “Galectin-9 Interacts With PD-1 and TIM-3 to Regulate T Cell Death and Is a Target for Cancer Immunotherapy,” Nature Communications 12, no. 1 (2021): 832.

[114] S. Huang, D. Liu, J. Sun, et al., “Tim-3 Regulates Sepsis-Induced Immunosuppression by Inhibiting the NF-κB Signaling Pathway in CD4 T Cells,” Molecular Therapy 30, no. 3 (2022): 1227–1238.

[115] L. Tang, G. Li, Y. Zheng, et al., “Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II,” Frontiers in Immunology 12 (2021): 770402.

[116] X. Jiang, T. Zhou, Y. Xiao, et al., “Tim-3 Promotes Tumor-Promoting M2 Macrophage Polarization by Binding to STAT1 and Suppressing the STAT1-miR-155 Signaling Axis,” Oncoimmunology 5, no. 9 (2016): e1211219.

[117] X. Jiang, J. Yu, Q. Shi, et al., “Tim-3 Promotes Intestinal Homeostasis in DSS Colitis by Inhibiting M1 Polarization of Macrophages,” Clinical Immunology 160, no. 2 (2015): 328–335.

[118] Á. de Mingo Pulido, K. Hänggi, D. P. Celias, et al., “The Inhibitory Receptor TIM-3 Limits Activation of the cGAS-STING Pathway in Intra-Tumoral Dendritic Cells by Suppressing Extracellular DNA Uptake,” Immunity 54, no. 6 (2021): 1154–1167.e7.

[119] X. Li, H. Lu, Y. Gu, et al., “Tim-3 Suppresses the Killing Effect of Vγ9Vδ2 T Cells on Colon Cancer Cells by Reducing Perforin and Granzyme B Expression,” Experimental Cell Research 386, no. 1 (2020): 111719.

[120] F. Liu, Y. Liu, and Z. Chen, “Tim-3 Expression and Its Role in Hepatocellular Carcinoma,” Journal of Hematology & Oncology 11, no. 1 (2018): 126.

[121] C. Zhang, H. Shen, T. Yang, et al., “A Single-Cell Analysis Reveals Tumor Heterogeneity and Immune Environment of Acral Melanoma,” Nature Communications 13, no. 1 (2022): 7250.

[122] L. C. Ndhlovu, S. Lopez-Vergès, J. D. Barbour, et al., “Tim-3 Marks Human Natural Killer Cell Maturation and Suppresses Cell-Mediated Cytotoxicity,” Blood 119, no. 16 (2012): 3734–3743.

[123] Á. de Mingo Pulido, A. Gardner, S. Hiebler, et al., “TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer,” Cancer Cell 33, no. 1 (2018): 60–74.e6.

[124] J. Fucikova, J. Rakova, M. Hensler, et al., “TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer,” Clinical Cancer Research 25, no. 15 (2019): 4820–4831.

[125] I. Datar, M. F. Sanmamed, J. Wang, et al., “Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis,” Clinical Cancer Research 25, no. 15 (2019): 4663–4673.

[126] Y. Kikushige, T. Miyamoto, J. Yuda, et al., “A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression,” Cell Stem Cell 17, no. 3 (2015): 341–352.

[127] R. Bouguerra, S. El Hajji, C. Wassmer, et al., “Hepatectomy Alters Adjuvant Anti-PD-1 Action in a Mouse Model of HCC but Does Not Compromise Neoadjuvant Efficacy,” Hepatology (2025).

[128] L. M. McLane, S. F. Ngiow, Z. Chen, et al., “Role of Nuclear Localization in the Regulation and Function of T-Bet and Eomes in Exhausted CD8 T Cells,” Cell Reports 35, no. 6 (2021): 109120.

[129] Y. Lai, S. Wang, T. Ren, et al., “TIGIT Deficiency Promotes Autoreactive CD4(+) T-Cell Responses Through a Metabolic‒Epigenetic Mechanism in Autoimmune Myositis,” Nature Communications 16, no. 1 (2025): 4502.

[130] N. Joller, A. Anderson, and V. Kuchroo, “LAG-3, TIM-3, and TIGIT: Distinct Functions in Immune Regulation,” Immunity 57, no. 2 (2024): 206–222.

[131] S. Liu, H. Zhang, M. Li, et al., “Recruitment of Grb2 and SHIP1 by the ITT-Like Motif of TIGIT Suppresses Granule Polarization and Cytotoxicity of NK Cells,” Cell Death and Differentiation 20, no. 3 (2013): 456–464.

[132] X. Huang, X. Zhang, E. Li, et al., “VISTA: An Immune Regulatory Protein Checking Tumor and Immune Cells in Cancer Immunotherapy,” Journal of Hematology & Oncology 13, no. 1 (2020): 83.

[133] C. Guy, D. M. Mitrea, P. Chou, et al., “LAG3 Associates With TCR-CD3 Complexes and Suppresses Signaling by Driving Co-Receptor-Lck Dissociation,” Nature Immunology 23, no. 5 (2022): 757–767.

[134] C. Solinas, C. Gu-Trantien, and K. Willard-Gallo, “The Rationale Behind Targeting the ICOS-ICOS Ligand Costimulatory Pathway in Cancer Immunotherapy,” ESMO Open 5, no. 1 (2020): e000544.

[135] R. Singh, Y. Kim, S. Lee, H. Eom, and B. K. Choi, “4-1BB Immunotherapy: Advances and Hurdles,” Experimental & Molecular Medicine 56, no. 1 (2024): 32–39.

[136] G. Liu and P. Luo, “Targeting CD137 (4-1BB) Towards Improved Safety and Efficacy for Cancer Immunotherapy,” Frontiers in Immunology 14 (2023): 1208788.

[137] E. Guttman-Yassky, M. Croft, B. Geng, et al., “The Role of OX40 Ligand/OX40 Axis Signalling in Atopic Dermatitis,” British Journal of Dermatology 191, no. 4 (2024): 488–496.

[138] B. Thapa, S. Kato, D. Nishizaki, et al., “OX40/OX40 Ligand and Its Role in Precision Immune Oncology,” Cancer and Metastasis Reviews 43, no. 3 (2024): 1001–1013.

[139] Y. Zhou, A. Richmond, and C. Yan, “Harnessing the Potential of CD40 Agonism in Cancer Therapy,” Cytokine & Growth Factor Reviews 75 (2024): 40–56.

[140] H. Ledford, “Melanoma Drug Wins US Approval,” Nature 471, no. 7340 (2011): 561.

[141] C. Robert, G. V. Long, B. Brady, et al., “Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma,” Journal of Clinical Oncology 38, no. 33 (2020): 3937–3946.

[142] H. Borghaei, L. Paz-Ares, L. Horn, et al., “Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer,” New England Journal of Medicine 373, no. 17 (2015): 1627–1639.

[143] C. Robert, J. Schachter, G. V. Long, et al., “Pembrolizumab Versus Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 372, no. 26 (2015): 2521–2532.

[144] M. Reck, D. Rodríguez-Abreu, A. G. Robinson, et al., “Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer,” New England Journal of Medicine 375, no. 19 (2016): 1823–1833.

[145] A. Rittmeyer, F. Barlesi, D. Waterkamp, et al., “Atezolizumab Versus Docetaxel in Patients With Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial,” Lancet 389, no. 10066 (2017): 255–265.

[146] R. L. Ferris, G. Blumenschein, J. Fayette, et al., “Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck,” New England Journal of Medicine 375, no. 19 (2016): 1856–1867.

[147] R. J. Motzer, B. Escudier, D. F. McDermott, et al., “Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma,” New England Journal of Medicine 373, no. 19 (2015): 1803–1813.

[148] A. Betof Warner, J. S. Palmer, A. N. Shoushtari, et al., “Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade,” Journal of Clinical Oncology 38, no. 15 (2020): 1655–1663.

[149] F. Garrido, N. Aptsiauri, E. M. Doorduijn, A. M. Garcia Lora, and T. van Hall, “The Urgent Need to Recover MHC Class I in Cancers for Effective Immunotherapy,” Current Opinion in Immunology 39 (2016): 44–51.

[150] F. Exposito, M. Redrado, M. Houry, et al., “PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells,” Cancer Research 83, no. 15 (2023): 2513–2526.

[151] H. Harb, E. Stephen-Victor, E. Crestani, et al., “A Regulatory T Cell Notch4-GDF15 Axis Licenses Tissue Inflammation in Asthma,” Nature Immunology 21, no. 11 (2020): 1359–1370.

[152] Z. Gong, Q. Jia, J. Chen, et al., “Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma,” Journal of Thoracic Oncology 14, no. 5 (2019): 857–866.

[153] M. Borgeaud, J. Sandoval, M. Obeid, et al., “Novel Targets for Immune-Checkpoint Inhibition in Cancer,” Cancer Treatment Reviews 120 (2023): 102614.

[154] C. Chen, F. Zhao, J. Peng, et al., “Soluble Tim-3 Serves as a Tumor Prognostic Marker and Therapeutic Target for CD8(+) T Cell Exhaustion and Anti-PD-1 Resistance,” Cell Reports Medicine 5, no. 8 (2024): 101686.

[155] M. A. Curran, W. Montalvo, H. Yagita, and J. P. Allison, “PD-1 and CTLA-4 Combination Blockade Expands Infiltrating T Cells and Reduces Regulatory T and Myeloid Cells Within B16 Melanoma Tumors,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 9 (2010): 4275–4280.

[156] J. D. Wolchok, H. Kluger, M. K. Callahan, et al., “Nivolumab Plus Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 369, no. 2 (2013): 122–133.

[157] J. Larkin, V. Chiarion-Sileni, R. Gonzalez, et al., “Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 381, no. 16 (2019): 1535–1546.

[158] J. D. Wolchok, V. Chiarion-Sileni, P. Rutkowski, et al., “Final, 10-Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 392, no. 1 (2025): 11–22.

[159] N. Tannir, L. Albigès, D. McDermott, et al., “Nivolumab Plus Ipilimumab Versus Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma: Extended 8-Year Follow-Up Results of Efficacy and Safety From the Phase III CheckMate 214 Trial,” Annals of Oncology 35, no. 11 (2024): 1026–1038.

[160] I. Melero, T. Yau, Y. Kang, et al., “Nivolumab Plus Ipilimumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: 5-Year Results From CheckMate 040,” Annals of Oncology 35, no. 6 (2024): 537–548.

[161] K. Kato, Y. Doki, I. Chau, et al., “Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (CheckMate 648): 29-Month Follow-Up From a Randomized, Open-Label, Phase III Trial,” Cancer Medicine 13, no. 9 (2024): e7235.

[162] B. Sangro, S. Chan, R. Kelley, et al., “Four-Year Overall Survival Update From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma,” Annals of Oncology 35, no. 5 (2024): 448–457.

[163] M. D. Hellmann, N. A. Rizvi, J. W. Goldman, et al., “Nivolumab Plus Ipilimumab as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer (CheckMate 012): Results of an Open-Label, Phase 1, Multicohort Study,” The Lancet Oncology 18, no. 1 (2017): 31–41.

[164] N. Ready, M. D. Hellmann, M. M. Awad, et al., “First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers,” Journal of Clinical Oncology 37, no. 12 (2019): 992–1000.

[165] J. R. Brahmer, J. Lee, T. Ciuleanu, et al., “Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227,” Journal of Clinical Oncology 41, no. 6 (2023): 1200–1212.

[166] K. Nutsch, K. L. Banta, T. D. Wu, et al., “TIGIT and PD-L1 Co-Blockade Promotes Clonal Expansion of Multipotent, Non-Exhausted Antitumor T Cells by Facilitating Co-Stimulation,” Nature Cancer 5, no. 12 (2024): 1834–1851.

[167] H. A. Tawbi, D. Schadendorf, E. J. Lipson, et al., “Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma,” New England Journal of Medicine 386, no. 1 (2022): 24–34.

[168] G. V. Long, E. J. Lipson, F. S. Hodi, et al., “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data,” Journal of Clinical Oncology 42, no. 33 (2024): 3926–3934.

[169] J. Niu, C. Maurice-Dror, D. Lee, et al., “First-in-Human Phase 1 Study of the Anti-TIGIT Antibody Vibostolimab as Monotherapy or With Pembrolizumab for Advanced Solid Tumors, Including Non-Small-Cell Lung Cancer(☆),” Annals of Oncology 33, no. 2 (2022): 169–180.

[170] R. Dummer, C. Robert, R. A. Scolyer, et al., “Neoadjuvant Anti-PD-1 Alone or in Combination With Anti-TIGIT or an Oncolytic Virus in Resectable Stage IIIB-D Melanoma: A Phase 1/2 Trial,” Nature Medicine 31, no. 1 (2025): 144–151.

[171] D. Rodriguez-Abreu, J. Bosch-Barrera, J. E. Gray, et al., “STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With no Actionable Gene Alterations,” Clinical Lung Cancer 25, no. 3 (2024): 274–279.

[172] J. Sun, X. Zhang, L. Xue, et al., “Structural Insights Into the Unique pH-Responsive Characteristics of the Anti-TIGIT Therapeutic Antibody Ociperlimab,” Structure 32, no. 5 (2024): 550–561.e5.

[173] S. Frentzas, S. Kao, R. Gao, et al., “AdvanTIG-105: A Phase I Dose Escalation Study of the Anti-TIGIT Monoclonal Antibody Ociperlimab in Combination With Tislelizumab in Patients With Advanced Solid Tumors,” Journal for ImmunoTherapy of Cancer 11, no. 10 (2023): e005829.

[174] O. Hamid, M. Gutierrez, I. Mehmi, et al., “A Phase 1/2 Study of Retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) Combination Therapy in Patients (Pts) With Advanced Solid Tumors,” Journal of Clinical Oncology 41, no. 16_suppl (2023): 2599–2599.

[175] J. Chauvin, O. Pagliano, J. Fourcade, et al., “TIGIT and PD-1 Impair Tumor Antigen-Specific CD8⁺ T Cells in Melanoma Patients,” Journal of Clinical Investigation 125, no. 5 (2015): 2046–2058.

[176] E. Chiang and I. Mellman, “TIGIT-CD226-PVR Axis: Advancing Immune Checkpoint Blockade for Cancer Immunotherapy,” Journal for ImmunoTherapy of Cancer 10, no. 4 (2022): e004711.

[177] D. Piovesan, A. E. de Groot, S. Cho, et al., “Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity Without Depleting Regulatory T Cells,” Cancer Research 84, no. 12 (2024): 1978–1995.

[178] L. Galluzzi, E. Guilbaud, D. Schmidt, G. Kroemer, and F. M. Marincola, “Targeting Immunogenic Cell Stress and Death for Cancer Therapy,” Nature Reviews Drug Discovery 23, no. 6 (2024): 445–460.

[179] Z. Li, X. Lai, S. Fu, et al., “Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 9, no. 22 (2022): e2201734.

[180] N. Li, Y. Li, J. Li, S. Tang, H. Gao, and Y. Li, “Correlation of the Abundance of MDSCs, Tregs, PD-1, and PD-L1 With the Efficacy of Chemotherapy and Prognosis in Gastric Cancer,” Laboratory Medicine 56, no. 3 (2024): 259–270.

[181] A. Goyal, J. Bauer, J. Hey, et al., “DNMT and HDAC Inhibition Induces Immunogenic Neoantigens From Human Endogenous Retroviral Element-Derived Transcripts,” Nature Communications 14, no. 1 (2023): 6731.

[182] L. Zhang, C. Zhou, S. Zhang, et al., “Chemotherapy Reinforces Anti-Tumor Immune Response and Enhances Clinical Efficacy of Immune Checkpoint Inhibitors,” Frontiers in Oncology 12 (2022): 939249.

[183] Y. Zhang, H. Chen, H. Mo, et al., “Distinct Cellular Mechanisms Underlie Chemotherapies and PD-L1 Blockade Combinations in Triple-Negative Breast Cancer,” Cancer Cell 43, no. 3 (2025): 446–463.e7.

[184] C. J. Langer, S. M. Gadgeel, H. Borghaei, et al., “Carboplatin and Pemetrexed With or Without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study,” The Lancet Oncology 17, no. 11 (2016): 1497–1508.

[185] M. C. Garassino, S. Gadgeel, E. Esteban, et al., “Patient-Reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients With Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial,” The Lancet Oncology 21, no. 3 (2020): 387–397.

[186] J. Chao, C. S. Fuchs, K. Shitara, et al., “Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials,” JAMA Oncology 7, no. 6 (2021): 895–902.

[187] S. Y. Rha, D. Oh, P. Yañez, et al., “Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer (KEYNOTE-859): A Multicentre, Randomised, Double-Blind, Phase 3 Trial,” The Lancet Oncology 24, no. 11 (2023): 1181–1195.

[188] J. Xu, H. Jiang, Y. Pan, et al., “Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial,” Jama 330, no. 21 (2023): 2064–2074.

[189] Y. K. Kang, M. Terashima, Y. W. Kim, et al., “Adjuvant Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Stage III Gastric or Gastro-Oesophageal Junction Cancer After Gastrectomy With D2 or More Extensive Lymph-Node Dissection (ATTRACTION-5): A Randomised, Multicentre, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet Gastroenterology and Hepatology 9, no. 8 (2024): 705–717.

[190] K. Shitara, S. Y. Rha, L. S. Wyrwicz, et al., “Neoadjuvant and Adjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced Gastric or Gastro-Oesophageal Cancer (KEYNOTE-585): An Interim Analysis of the Multicentre, Double-Blind, Randomised Phase 3 Study,” The Lancet Oncology 25, no. 2 (2024): 212–224.

[191] C. J. Hoimes, T. W. Flaig, M. I. Milowsky, et al., “Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer,” Journal of Clinical Oncology 41, no. 1 (2023): 22–31.

[192] M. S. van der Heijden, G. Sonpavde, T. Powles, et al., “Nivolumab Plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma,” New England Journal of Medicine 389, no. 19 (2023): 1778–1789.

[193] J. Zhai, X. Gu, Y. Liu, Y. Hu, Y. Jiang, and Z. Zhang, “Chemotherapeutic and Targeted Drugs-Induced Immunogenic Cell Death in Cancer Models and Antitumor Therapy: An Update Review,” Frontiers in Pharmacology 14 (2023): 1152934.

[194] A. Basu, A. Hoerning, D. Datta, et al., “Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN-Gamma Production,” Journal of Immunology 184, no. 2 (2010): 545–549.

[195] S. Karakhanova, J. Link, M. Heinrich, et al., “Characterization of Myeloid Leukocytes and Soluble Mediators in Pancreatic Cancer: Importance of Myeloid-Derived Suppressor Cells,” Oncoimmunology 4, no. 4 (2015): e998519.

[196] S. Peng, R. Wang, X. Zhang, et al., “EGFR-TKI Resistance Promotes Immune Escape in Lung Cancer via Increased PD-L1 Expression,” Molecular Cancer 18, no. 1 (2019): 165.

[197] D. Munn and A. Mellor, “IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance,” Trends in Immunology 37, no. 3 (2016): 193–207.

[198] R. S. Finn, S. Qin, M. Ikeda, et al., “Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma,” New England Journal of Medicine 382, no. 20 (2020): 1894–1905.

[199] P. A. Ascierto, D. Stroyakovskiy, H. Gogas, et al., “Overall Survival With First-Line Atezolizumab in Combination With Vemurafenib and Cobimetinib in BRAF(V600) Mutation-Positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study,” The Lancet Oncology 24, no. 1 (2023): 33–44.

[200] C. Cai, I. Yunusa, and A. Tarhini, “Estimated Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma,” JAMA Network Open 4, no. 11 (2021): e2132262.

[201] R. Gutzmer, D. Stroyakovskiy, H. Gogas, et al., “Atezolizumab, Vemurafenib, and Cobimetinib as First-Line Treatment for Unresectable Advanced BRAF(V600) Mutation-Positive Melanoma (IMspire150): Primary Analysis of the Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet 395, no. 10240 (2020): 1835–1844.

[202] C. Robert, K. Lewis, R. Gutzmer, et al., “Biomarkers of Treatment Benefit With Atezolizumab Plus Vemurafenib Plus Cobimetinib in BRAF(V600) Mutation-Positive Melanoma,” Annals of Oncology 33, no. 5 (2022): 544–555.

[203] J. Saal, M. Eckstein, M. Ritter, et al., “Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy,” JAMA Oncology 11, no. 2 (2025): 154–161.

[204] X. Chen, A. Gao, F. Zhang, et al., “ILT4 Inhibition Prevents TAM- and Dysfunctional T Cell-Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in NSCLC With EGFR Activation,” Theranostics 11, no. 7 (2021): 3392–3416.

[205] E. Sugiyama, Y. Togashi, Y. Takeuchi, et al., “Blockade of EGFR Improves Responsiveness to PD-1 Blockade in EGFR-Mutated Non-Small Cell Lung Cancer,” Science Immunology 5, no. 43 (2020): eaav3937.

[206] Y. Zhao, G. Chen, J. Chen, et al., “AK112, a Novel PD-1/VEGF Bispecific Antibody, in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): An Open-Label, Multicenter, Phase II Trial,” EClinicalMedicine 62 (2023): 102106.

[207] J. C. Yang, S. M. Gadgeel, L. V. Sequist, et al., “Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation,” Journal of Thoracic Oncology 14, no. 3 (2019): 553–559.

[208] N. Nogami, F. Barlesi, M. A. Socinski, et al., “IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain,” Journal of Thoracic Oncology 17, no. 2 (2022): 309–323.

[209] M. A. Socinski, M. Nishio, R. M. Jotte, et al., “IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC,” Journal of Thoracic Oncology 16, no. 11 (2021): 1909–1924.

[210] L. Rimassa, R. Finn, and B. Sangro, “Combination Immunotherapy for Hepatocellular Carcinoma,” Journal of Hepatology 79, no. 2 (2023): 506–515.

[211] A. Venniyoor, “Synergism Between Anti-Angiogenic and Immune Checkpoint Inhibitor Drugs: A Hypothesis,” Medical Hypotheses 146 (2021): 110399.

[212] F. A. Büttner, S. Winter, V. Stühler, et al., “A Novel Molecular Signature Identifies Mixed Subtypes in Renal Cell Carcinoma With Poor Prognosis and Independent Response to Immunotherapy,” Genome Medicine 14, no. 1 (2022): 105.

[213] R. H. I. Andtbacka, B. Curti, G. A. Daniels, et al., “Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma,” Journal of Clinical Oncology 39, no. 34 (2021): 3829–3838.

[214] Coxsackievirus A21 Synergizes With Checkpoint Inhibitors. Cancer Discovery 2017. 7(6): p. Of9.

[215] A. W. Silk, S. J. O'Day, H. L. Kaufman, et al., “A Phase 1b Single-Arm Trial of Intratumoral Oncolytic Virus V937 in Combination With Pembrolizumab in Patients With Advanced Melanoma: Results From the CAPRA Study,” Cancer Immunology, Immunotherapy 72, no. 6 (2023): 1405–1415.

[216] C. M. Rudin, H. S. Pandha, M. Zibelman, et al., “Phase 1, Open-Label, Dose-Escalation Study on the Safety, Pharmacokinetics, and Preliminary Efficacy of Intravenous Coxsackievirus A21 (V937), With or Without Pembrolizumab, in Patients With Advanced Solid Tumors,” Journal for ImmunoTherapy of Cancer 11, no. 1 (2023): e005007.

[217] L. Yi, Z. Ning, L. Xu, et al., “The Combination Treatment of Oncolytic Adenovirus H101 With Nivolumab for Refractory Advanced Hepatocellular Carcinoma: An Open-Label, Single-Arm, Pilot Study,” ESMO Open 9, no. 2 (2024): 102239.

[218] M. McLaughlin, E. C. Patin, M. Pedersen, et al., “Inflammatory Microenvironment Remodelling by Tumour Cells After Radiotherapy,” Nature Reviews Cancer 20, no. 4 (2020): 203–217.

[219] W. Zhen, R. Weichselbaum, and W. Lin, “Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy,” Advanced Materials 35, no. 21 (2023): e2206370.

[220] O. Ozpiskin, L. Zhang, and J. Li, “Immune Targets in the Tumor Microenvironment Treated by Radiotherapy,” Theranostics 9, no. 5 (2019): 1215–1231.

[221] M. Jarosz-Biej, R. Smolarczyk, T. Cichoń, and N. Kułach, “Tumor Microenvironment as a “Game Changer” in Cancer Radiotherapy,” International Journal of Molecular Sciences 20, no. 13 (2019): 3212.

[222] M. Yang, J. Li, P. Gu, and X. Fan, “The Application of Nanoparticles in Cancer Immunotherapy: Targeting Tumor Microenvironment,” Bioactive Materials 6, no. 7 (2021): 1973–1987.

[223] M. Ashrafizadeh, B. Farhood, A. E. Musa, S. Taeb, and M. Najafi, “The Interactions and Communications in Tumor Resistance to Radiotherapy: Therapy Perspectives,” International Immunopharmacology 87 (2020): 106807.

[224] M. Spaas, N. Sundahl, V. Kruse, et al., “Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial,” JAMA Oncology 9, no. 9 (2023): 1205–1213.

[225] P. Zhou, D. Chen, B. Zhu, et al., “Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma,” Frontiers in Immunology 11 (2020): 594212.

[226] F. Tong, Y. Sun, Y. Zhu, et al., “Making “Cold” Tumors “Hot”- Radiotherapy Remodels the Tumor Immune Microenvironment of Pancreatic Cancer to Benefit From Immunotherapy: A Case Report,” Frontiers in Immunology 14 (2023): 1277810.

[227] L. Sevenich, “Turning “Cold” Into “Hot” Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers,” Frontiers in Oncology 9 (2019): 163.

[228] Y. Ding, Y. Feng, Y. Ye, et al., “High and Low Dose Radiotherapy Combined With ICIs for MSS Colorectal Cancer Patients With Liver Metastases: A Phase I Study (HaRyPOT),” Frontiers in Oncology 15 (2025): 1503517.

[229] W. Wu, T. Chia, J. Lu, et al., “IL-2Rα-Biased Agonist Enhances Antitumor Immunity by Invigorating Tumor-Infiltrating CD25(+)CD8(+) T Cells,” Nature Cancer 4, no. 9 (2023): 1309–1325.

[230] L. Codarri Deak, V. Nicolini, M. Hashimoto, et al., “PD-1-cis IL-2R Agonism Yields Better Effectors From Stem-Like CD8(+) T Cells,” Nature 610, no. 7930 (2022): 161–172.

[231] P. Monk, E. Lam, A. Mortazavi, et al., “A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma,” Journal of Immunotherapy 37, no. 3 (2014): 180–186.

[232] T. Flaadt, R. L. Ladenstein, M. Ebinger, et al., “Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial,” Journal of Clinical Oncology 41, no. 17 (2023): 3135–3148.

[233] J. M. Wrangle, V. Velcheti, M. R. Patel, et al., “ALT-803, an IL-15 Superagonist, in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Non-Randomised, Open-Label, Phase 1b Trial,” The Lancet Oncology 19, no. 5 (2018): 694–704.

[234] T. J. Herzog, J. L. Hays, J. N. Barlin, et al., “ARTISTRY-7: Phase III Trial of Nemvaleukin Alfa Plus Pembrolizumab vs Chemotherapy for Platinum-Resistant Ovarian Cancer,” Future Oncology 19, no. 23 (2023): 1577–1591.

[235] R. Nguyen, E. Doubrovina, C. M. Mousset, et al., “Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy,” Clinical Cancer Research 30, no. 8 (2024): 1555–1566.

[236] T. J. Guzik, R. Nosalski, P. Maffia, and G. R. Drummond, “Immune and Inflammatory Mechanisms in Hypertension,” Nature Reviews Cardiology 21, no. 6 (2024): 396–416.

[237] R. M. Awad, Y. De Vlaeminck, F. Meeus, et al., “In Vitro Modelling of Local Gene Therapy With IL-15/IL-15Rα and a PD-L1 Antagonist in Melanoma Reveals an Interplay Between NK Cells and CD4(+) T Cells,” Scientific Reports 13, no. 1 (2023): 18995.

[238] S. Martomo and J. Patel, “Evaluation of the Clinical Molecule Anti-Human-PD-L1/IL-15 KD033 in the Human-PD-1/PD-L1-Expressing Murine Model Demonstrates PD-L1 Targeting of IL-15 in Vivo,” Cancer Immunology, Immunotherapy 72, no. 6 (2023): 1941–1950.

[239] S. A. Martomo, D. Lu, Z. Polonskaya, et al., “Single-Dose Anti-PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity With Robust Tumor-Immune Gene Signatures and Memory Responses,” Molecular Cancer Therapeutics 20, no. 2 (2021): 347–356.

[240] Y. Shi, W. Zheng, K. Yang, et al., “Intratumoral Accumulation of Gut Microbiota Facilitates CD47-Based Immunotherapy via STING Signaling,” Journal of Experimental Medicine 217, no. 5 (2020): e20192282.

[241] S. F. Erttmann, P. Swacha, K. M. Aung, et al., “The Gut Microbiota Prime Systemic Antiviral Immunity via the cGAS-STING-IFN-I Axis,” Immunity 55, no. 5 (2022): 847–861.e10.

[242] J. Gao, X. Zhao, S. Hu, et al., “Gut Microbial DL-Endopeptidase Alleviates Crohn's Disease via the NOD2 Pathway,” Cell Host & Microbe 30, no. 10 (2022): 1435–1449.e9.

[243] J. Wang, N. Zhu, X. Su, Y. Gao, and R. Yang, “Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis,” Cells 12, no. 5 (2023): 793.

[244] I. Sieminska and J. Baran, “Myeloid-Derived Suppressor Cells in Colorectal Cancer,” Frontiers in Immunology 11 (2020): 1526.

[245] Y. Che, S. Fu, H. Wang, et al., “Correlation of the Gut Microbiota and Antitumor Immune Responses Induced by a Human Papillomavirus Therapeutic Vaccine,” ACS Infectious Diseases 8, no. 12 (2022): 2494–2504.

[246] R. C. Simpson, E. R. Shanahan, R. A. Scolyer, and G. V. Long, “Towards Modulating the Gut Microbiota to Enhance the Efficacy of Immune-Checkpoint Inhibitors,” Nature Reviews Clinical Oncology 20, no. 10 (2023): 697–715.

[247] B. Routy, E. Le Chatelier, L. Derosa, et al., “Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors,” Science 359, no. 6371 (2018): 91–97.

[248] Y. Lu, X. Yuan, M. Wang, et al., “Gut Microbiota Influence Immunotherapy Responses: Mechanisms and Therapeutic Strategies,” Journal of Hematology & Oncology 15, no. 1 (2022): 47.

[249] W. Cheng, C. Wu, and J. Yu, “The Role of Gut Microbiota in Cancer Treatment: Friend or Foe?,” Gut 69, no. 10 (2020): 1867–1876.

[250] B. Routy, J. G. Lenehan, W. H. Miller, et al., “Fecal Microbiota Transplantation Plus Anti-PD-1 Immunotherapy in Advanced Melanoma: A Phase I Trial,” Nature Medicine 29, no. 8 (2023): 2121–2132.

[251] D. Davar, A. K. Dzutsev, J. A. McCulloch, et al., “Fecal Microbiota Transplant Overcomes Resistance to Anti-PD-1 Therapy in Melanoma Patients,” Science 371, no. 6529 (2021): 595–602.

[252] E. N. Baruch, I. Youngster, G. Ben-Betzalel, et al., “Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients,” Science 371, no. 6529 (2021): 602–609.

[253] K. Zarrabi, U. Vaishampayan, and P. Barata, “Enhancing the Immunogenicity of Nivolumab Plus Ipilimumab With Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma,” European Urology Focus 10, no. 6 (2024): 879–881.

[254] R. Barragan-Carrillo, Z. Zengin, and S. Pal, “Microbiome Modulation for the Treatment of Solid Neoplasms,” Journal of Clinical Oncology 43, no. 24 (2025): 2734–2738.

[255] M. Lv, M. Chen, R. Zhang, et al., “Manganese Is Critical for Antitumor Immune Responses via cGAS-STING and Improves the Efficacy of Clinical Immunotherapy,” Cell Research 30, no. 11 (2020): 966–979.

[256] H. Kim, J. Y. Hong, W. Jeon, J. Lee, Y. J. Lee, and I. Ha, “Melittin Regulates Iron Homeostasis and Mediates Macrophage Polarization in Rats With Lumbar Spinal Stenosis,” Biomedicine & Pharmacotherapy 156 (2022): 113776.

[257] P. Handa, S. Thomas, V. Morgan-Stevenson, et al., “Iron Alters Macrophage Polarization Status and Leads to Steatohepatitis and Fibrogenesis,” Journal of Leukocyte Biology 105, no. 5 (2019): 1015–1026.

[258] F. Voli, E. Valli, L. Lerra, et al., “Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion,” Cancer Research 80, no. 19 (2020): 4129–4144.

[259] F. Gao, W. You, L. Zhang, et al., “Copper Chelate Targeting Externalized Phosphatidylserine Inhibits PD-L1 Expression and Enhances Cancer Immunotherapy,” Journal of the American Chemical Society 147, no. 7 (2025): 5796–5807.

[260] C. Kanellopoulou, A. B. George, E. Masutani, et al., “Mg(2+) Regulation of Kinase Signaling and Immune Function,” Journal of Experimental Medicine 216, no. 8 (2019): 1828–1842.

[261] L. Butterfield and Y. Najjar, “Immunotherapy Combination Approaches: Mechanisms, Biomarkers and Clinical Observations,” Nature Reviews Immunology 24, no. 6 (2024): 399–416.

[262] C. Luchini, F. Bibeau, M. Ligtenberg, et al., “ESMO Recommendations on Microsatellite Instability Testing for Immunotherapy in Cancer, and Its Relationship With PD-1/PD-L1 Expression and Tumour Mutational Burden: A Systematic Review-Based Approach,” Annals of Oncology 30, no. 8 (2019): 1232–1243.

[263] A. M. Goodman, S. Kato, L. Bazhenova, et al., “Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers,” Molecular Cancer Therapeutics 16, no. 11 (2017): 2598–2608.

[264] J. Shim, H. Kim, H. Cha, et al., “HLA-Corrected Tumor Mutation Burden and Homologous Recombination Deficiency for the Prediction of Response to PD-(L)1 Blockade in Advanced Non-Small-Cell Lung Cancer Patients,” Annals of Oncology 31, no. 7 (2020): 902–911.

[265] F. Huber and M. Bassani-Sternberg, “Defects in Antigen Processing and Presentation: Mechanisms, Immune Evasion and Implications for Cancer Vaccine Development,” Nature Reviews Immunology 26, no. 1 (2026): 23–34.

[266] F. Wang, G. Chen, M. Qiu, et al., “Neoadjuvant Treatment of IBI310 Plus Sintilimab in Locally Advanced MSI-H/dMMR Colon Cancer: A Randomized Phase 1b Study,” Cancer Cell 43, no. 10 (2025): 1958–1967.e2.

[267] Z. Yu, G. Yang, J. Yue, et al., “Case Report: Successful Treatment of a Case of Lynch Syndrome With Double Primary Ovarian and Rectal Cancer,” Frontiers in Oncology 15 (2025): 1534979.

[268] R. Li, Y. Lin, X. Shen, et al., “Case Report: Failed Response to anti-PD-1 Immunotherapy in a Colon Cancer Patient With High Microsatellite Instability,” Frontiers in Oncology 15 (2025): 1636122.

[269] F. Davoudi, A. Moradi, H. Sadeghirad, and A. Kulasinghe, “Tissue Biomarkers of Immune Checkpoint Inhibitor Therapy,” Immunology and Cell Biology 102, no. 3 (2024): 179–193.

[270] Y. Liu, H. Jiang, Z. Fang, et al., “Progenitor-Exhausted T Cell as Prognostic Indicator in Esophageal Squamous Cell Carcinoma: Illuminating Their Key Contribution to Tumor Immunity,” Frontiers in Immunology 16 (2025): 1659077.

[271] M. Mulholland, A. Chalou, S. H. A. Andersson, et al., “Progenitor Exhausted PD-1(+) T Cells Are Cellular Targets of Immune Checkpoint Inhibition in Atherosclerosis,” Nature Cardiovascular Research 4, no. 10 (2025): 1311–1328.

[272] J. Fumet, C. Latour, L. Nuttin, et al., “Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal Cancer,” Cancer Research 86, no. 3 (2025): 785–801.

[273] N. Y. Lin, S. Fukuoka, S. Koyama, et al., “Microbiota-Driven Antitumour Immunity Mediated by Dendritic Cell Migration,” Nature 644, no. 8078 (2025): 1058–1068.

[274] Y. Gao, P. Xu, D. Sun, et al., “Faecalibacterium Prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade,” Cancer Research 83, no. 22 (2023): 3710–3725.

[275] A. C. Huang, M. A. Postow, R. J. Orlowski, et al., “T-Cell Invigoration to Tumour Burden Ratio Associated With anti-PD-1 Response,” Nature 545, no. 7652 (2017): 60–65.

[276] V. Anagnostou, C. Ho, G. Nicholas, et al., “ctDNA Response After Pembrolizumab in Non-Small Cell Lung Cancer: Phase 2 Adaptive Trial Results,” Nature Medicine 29, no. 10 (2023): 2559–2569.

[277] H. Halse, A. J. Colebatch, P. Petrone, et al., “Multiplex Immunohistochemistry Accurately Defines the Immune Context of Metastatic Melanoma,” Scientific Reports 8, no. 1 (2018): 11158.

[278] C. Niveau, M. Cettour-Cave, S. Mouret, et al., “MCT1 Lactate Transporter Blockade Re-Invigorates Anti-Tumor Immunity Through Metabolic Rewiring of Dendritic Cells in Melanoma,” Nature Communications 16, no. 1 (2025): 1083.

[279] R. J. Argüello, A. J. Combes, R. Char, et al., “SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism With Single-Cell Resolution,” Cell Metabolism 32, no. 6 (2020): 1063–1075.e7.

[280] E. A. Chong, C. Alanio, J. Svoboda, et al., “Pembrolizumab for B-Cell Lymphomas Relapsing After or Refractory to CD19-Directed CAR T-Cell Therapy,” Blood 139, no. 7 (2022): 1026–1038.

[281] M. Pan and B. Li, “T Cell Receptor Convergence Is an Indicator of Antigen-Specific T Cell Response in Cancer Immunotherapies,” Elife 11 (2022): e81952.

[282] M. Sacco, et al., “Deep Learning Discriminates Thymic Epithelial Tumors' Histological Subtypes Using Digital Pathology,” Annals of Oncology (2025).

[283] S. Andani, B. Chen, J. Ficek-Pascual, et al., “Histopathology-Based Protein Multiplex Generation Using Deep Learning,” Nature Machine Intelligence 7, no. 8 (2025): 1292–1307.

[284] G. De Velasco, Y. Je, D. Bossé, et al., “Comprehensive Meta-Analysis of Key Immune-Related Adverse Events From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients,” Cancer Immunology Research 5, no. 4 (2017): 312–318.

[285] I. Puzanov, A. Diab, K. Abdallah, et al., “Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group,” Journal for ImmunoTherapy of Cancer 5, no. 1 (2017): 95.

[286] Q. Yin, L. Wu, L. Han, et al., “Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Review,” Frontiers in Immunology 14 (2023): 1167975.

[287] S. Pichon, G. Zebian, C. Bureau, et al., “Life-Threatening Immune-Related Adverse Events in the Intensive Care Unit: A Narrative Review,” Intensive Care Medicine 51, no. 12 (2025): 2289–2304.

[288] S. Iwama, T. Kobayashi, and H. Arima, “Management, Biomarkers and Prognosis in People Developing Endocrinopathies Associated With Immune Checkpoint Inhibitors,” Nature Reviews Endocrinology 21, no. 5 (2025): 289–300.

[289] S. Iwama, A. De Remigis, M. K. Callahan, S. F. Slovin, J. D. Wolchok, and P. Caturegli, “Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody,” Science Translational Medicine 6, no. 230 (2014): 230ra45.

[290] A. Ribas, R. Dummer, I. Puzanov, et al., “Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy,” Cell 170, no. 6 (2017): 1109–1119.e10.

[291] T. Nopsopon, M. Wu, and D. Sardana, “Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score,” JAMA Oncology 8, no. 7 (2022): 1072.

[292] G. Zhou, N. Zhang, K. Meng, and F. Pan, “Interaction Between Gut Microbiota and Immune Checkpoint Inhibitor-Related Colitis,” Frontiers in Immunology 13 (2022): 1001623.

[293] A. Diab, H. Gogas, S. Sandhu, et al., “Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results,” Journal of Clinical Oncology 41, no. 30 (2023): 4756–4767.

[294] J. S. Weber, M. S. Carlino, A. Khattak, et al., “Individualised Neoantigen Therapy mRNA-4157 (V940) Plus Pembrolizumab Versus Pembrolizumab Monotherapy in Resected Melanoma (KEYNOTE-942): A Randomised, Phase 2b Study,” Lancet 403, no. 10427 (2024): 632–644.

[295] P. Abraham and D. Johnson, “Long-Term Toxicities of Immune Checkpoint Inhibitors,” Drugs 85, no. 12 (2025): 1535–1549.

[296] J. Wright, A. Powers, and D. Johnson, “Endocrine Toxicities of Immune Checkpoint Inhibitors,” Nature Reviews Endocrinology 17, no. 7 (2021): 389–399.

[297] A. Haugh and A. Daud, “Distinguishing Between Help and Harm: Helper T Cell Subsets and Immune-Related Adverse Events,” Journal of Clinical Investigation 134, no. 20 (2024): e184310.

[298] R. Reschke, R. J. Sullivan, E. J. Lipson, A. H. Enk, T. F. Gajewski, and J. C. Hassel, “Targeting Molecular Pathways to Control Immune Checkpoint Inhibitor Toxicities,” Trends in Immunology 46, no. 1 (2025): 61–73.

[299] Y. Hailemichael, D. H. Johnson, N. Abdel-Wahab, et al., “Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity,” Cancer Cell 40, no. 5 (2022): 509–523.e6.

[300] E. Perez-Ruiz, L. Minute, I. Otano, et al., “Prophylactic TNF Blockade Uncouples Efficacy and Toxicity in Dual CTLA-4 and PD-1 Immunotherapy,” Nature 569, no. 7756 (2019): 428–432.

[301] M. J. Walsh, L. R. Ali, P. Lenehan, et al., “Blockade of Innate Inflammatory Cytokines TNFα, IL-1β, or IL-6 Overcomes Virotherapy-Induced Cancer Equilibrium to Promote Tumor Regression,” Immunotherapy Advances 3, no. 1 (2023): ltad011.

[302] S. Wang and T. Chan, “Navigating Established and Emerging Biomarkers for Immune Checkpoint Inhibitor Therapy,” Cancer Cell 43, no. 4 (2025): 641–664.

[303] L. Jiang, C. You, Y. Xiao, et al., “Radiogenomic Analysis Reveals Tumor Heterogeneity of Triple-Negative Breast Cancer,” Cell Reports Medicine 3, no. 7 (2022): 100694.

[304] V. Pietrobon and F. Marincola, “Hypoxia and the Phenomenon of Immune Exclusion,” Journal of Translational Medicine 19, no. 1 (2021): 9.

[305] L. Munn and R. Jain, “Vascular Regulation of Antitumor Immunity,” Science 365, no. 6453 (2019): 544–545.

[306] M. Hutchings, F. Morschhauser, G. Iacoboni, et al., “Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial,” Journal of Clinical Oncology 39, no. 18 (2021): 1959–1970.

[307] G. Cartron, R. Houot, Y. Al Tabaa, et al., “Glofitamab in Refractory or Relapsed Diffuse Large B Cell Lymphoma After Failing CAR-T Cell Therapy: A Phase 2 LYSA Study,” Nature Cancer 6, no. 7 (2025): 1173–1183.

[308] G. Arena and R. Chiarle, “Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies,” Cancers (Basel) 17, no. 21 (2025): 3453.

[309] H. Kwon and C. Lee, “The Emergence of a New Paradigm With Signal 1 and Signal 2 T-Cell Engagers in Hematology,” Seminars in Hematology 62, no. 4 (2025): 245–254.

[310] T. Roider, B. J. Brinkmann, V. Kim, et al., “An Autologous Culture Model of Nodal B-Cell Lymphoma Identifies Ex Vivo Determinants of Response to Bispecific Antibodies,” Blood Advances 5, no. 23 (2021): 5060–5071.

[311] L. van Hooren, S. M. Handgraaf, D. J. Kloosterman, et al., “CD103(+) Regulatory T Cells Underlie Resistance to Radio-Immunotherapy and Impair CD8(+) T Cell Activation in Glioblastoma,” Nature Cancer 4, no. 5 (2023): 665–681.

[312] Z. Huang, J. Chen, T. Zhu, et al., “Cancer-Associated Fibroblasts in the Tumor Microenvironment: Heterogeneity, Crosstalk Mechanisms, and Therapeutic Implications,” Molecular Cancer 25, no. 1 (2025): 19.

[313] B. A. Helmink, S. M. Reddy, J. Gao, et al., “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response,” Nature 577, no. 7791 (2020): 549–555.

[314] W. Xu, C. Ma, W. Liu, et al., “Prognostic Value, DNA Variation and Immunologic Features of a Tertiary Lymphoid Structure-Related Chemokine Signature in Clear Cell Renal Cell Carcinoma,” Cancer Immunology, Immunotherapy 71, no. 8 (2022): 1923–1935.

[315] W. Xu, J. Lu, W. Liu, et al., “Heterogeneity in Tertiary Lymphoid Structures Predicts Distinct Prognosis and Immune Microenvironment Characterizations of Clear Cell Renal Cell Carcinoma,” Journal for ImmunoTherapy of Cancer 11, no. 12 (2023): e006667.

[316] W. Xu, J. Lu, X. Tian, et al., “Unveiling the Impact of Tertiary Lymphoid Structures on Immunotherapeutic Responses of Clear Cell Renal Cell Carcinoma,” MedComm 5, no. 1 (2024): e461.

[317] M. B. Hugaboom, L. V. Wirth, K. Street, et al., “Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma,” Cancer Discovery 15, no. 5 (2025): 948–968.

[318] P. Cakmak, J. H. Lun, A. Singh, et al., “Spatial Immune Profiling Defines a Subset of Human Gliomas With Functional Tertiary Lymphoid Structures,” Immunity 58, no. 11 (2025): 2847–2863.e8.

[319] G. Kellermann, N. Leulliot, J. Cherfils-Vicini, M. Blaud, and P. Brest, “Activated B-Cells Enhance Epitope Spreading to Support Successful Cancer Immunotherapy,” Frontiers in Immunology 15 (2024): 1382236.

[320] X. Sun, W. Liu, L. Sun, et al., “Maturation and Abundance of Tertiary Lymphoid Structures Are Associated With the Efficacy of Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer,” Journal for ImmunoTherapy of Cancer 10, no. 11 (2022): e005531.

[321] M. Chelvanambi, R. J. Fecek, J. L. Taylor, and W. J. Storkus, “STING Agonist-Based Treatment Promotes Vascular Normalization and Tertiary Lymphoid Structure Formation in the Therapeutic Melanoma Microenvironment,” Journal for ImmunoTherapy of Cancer 9, no. 2 (2021): e001906.

[322] M. Ukita, J. Hamanishi, H. Yoshitomi, et al., “CXCL13-Producing CD4+ T Cells Accumulate in the Early Phase of Tertiary Lymphoid Structures in Ovarian Cancer,” JCI Insight 7, no. 12 (2022): e157215.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.